Abstract: An aspect of the present disclosure estimates effort required for testing web services deployed in an enterprise system. In one embodiment, a configuration data specifying complexity levels of web service operations and a number of test cases required for each of the complexity levels is maintained. Upon receiving data specifying a web service (deployed in the enterprise system) sought to be tested, a definition of the web service is inspected to identify web service operations provided by the web service. For each web service operation, a complexity level is determined, and a corresponding number of test cases required to be prepared for the determined complexity level is identified by examining the configuration data. A total number of test cases that is required to be prepared for testing the web service is then computed based on the identified number of test cases for the web service operations of the web service.

Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Abstract: Adsorbent materials are disclosed, along with filter elements containing the adsorbent materials methods of using adsorbents to remove slioxane contaminants from a gas stream. The method includes providing an adsorbent material that has been washed with an acid and passing a gas through the adsorbent material so as to reduce siloxane levels in the gas. A filter element for reducing siloxane levels in a gas includes a first adsorbent material, the first adsorbent material comprising an acid-washed adsorbent; and a second adsorbent material, the second adsorbent material comprising an acid-impregnated adsorbent.

Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.

Abstract: Adsorbent materials are disclosed, along with filter elements containing the adsorbent materials methods of using adsorbents to remove siloxane contaminants from a gas stream. The method includes providing an adsorbent material that has been washed with an acid and passing a gas through the adsorbent material so as to reduce siloxane levels in the gas. A filter element for reducing siloxane levels in a gas includes a first adsorbent material, the first adsorbent material comprising an acid-washed adsorbent; and a second adsorbent material, the second adsorbent material comprising an acid-impregnated adsorbent.

Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.

Abstract: The present invention provides HA polypeptides (e.g., H1 HA polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to HA polypeptides (e.g., H1 HA polypeptides), and reagents and methods relating thereto. The present invention provides interfering agents that inhibit the binding of HA polypeptides (e.g., H1 HA polypeptides) to HA receptors, and reagents and methods relating thereto. The present invention provides compositions and methods for treating, preventing, and/or diagnosing influenza infection utilizing HA polypeptides, HA polypeptide binding agents, HA polypeptide interfering agents, and/or vaccine compositions comprising any of the foregoing.

Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Abstract: This disclosure relates to peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.

Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.

Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.

Abstract: The present invention provides HA polypeptides (e.g., H1 HA polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to HA polypeptides (e.g., H1 HA polypeptides), and reagents and methods relating thereto. The present invention provides interfering agents that inhibit the binding of HA polypeptides (e.g., H1 HA polypeptides) to HA receptors, and reagents and methods relating thereto. The present invention provides compositions and methods for treating, preventing, and/or diagnosing influenza infection utilizing HA polypeptides, HA polypeptide binding agents, HA polypeptide interfering agents, and/or vaccine compositions comprising any of the foregoing.

Abstract: A method of forming a hemming tool includes providing a computer generated model of a panel including a flange in an unhemmed position and of a hemming tool including a hemming surface. Hemming the flange with the hemming tool is virtually simulated in the computer generated model. At least one non-conformity is identified along the flange in the computer generated model after virtually simulating hemming. The computer generated model is then modified to a modified computer generated model by adjusting the flange to change the at least one defect. Hemming the flange in the unhemmed position with the hemming tool is then virtually simulated in the modified computer generated model in the modified computer generated model.

Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.

Abstract: Described herein are filter assemblies for removing high molecular weight organic components from liquefied petroleum gas, as well as methods for removing high molecular weight components from liquefied petroleum gases. The filter assemblies include an upstream carbon-containing filter media pack and a downstream filter media pack.

Abstract: A method of forming a hemming tool includes providing a computer generated model of a panel including a flange in an unhemmed position and of a hemming tool including a hemming surface. Hemming the flange with the hemming tool is virtually simulated in the computer generated model. At least one non-conformity is identified along the flange in the computer generated model after virtually simulating hemming. The computer generated model is then modified to a modified computer generated model by adjusting the flange to change the at least one defect. Hemming the flange in the unhemmed position with the hemming tool is then virtually simulated in the modified computer generated model in the modified computer generated model.

Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

Abstract: Described herein are filter assemblies for removing high molecular weight organic components from liquefied petroleum gas, as well as methods for removing high molecular weight components from liquefied petroleum gases. The filter assemblies include an upstream carbon-containing filter media pack and a downstream filter media pack.